Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Acasti Pharma Inc (ACST.VN)

Acasti Pharma Inc (ACST.VN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Acasti Pharma Submits FDA Meeting Request on Schedule, and FDA Meeting Expected in the Second Half of June

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate...

ACST : 0.3346 (-3.01%)
ACST.VN : 0.470 (-6.00%)
Acasti Pharma Awarded Notice of Allowance for Additional Composition of Matter and Method of Use Patents in the United States and Mexico

Patent upheld in Japan following opposition filings and subsequently allowed

ACST : 0.3346 (-3.01%)
ACST.VN : 0.470 (-6.00%)
Acasti Receives NASDAQ Notification Regarding Minimum Bid Requirements

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate...

ACST : 0.3346 (-3.01%)
ACST.VN : 0.470 (-6.00%)
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2020

Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre...

ACST : 0.3346 (-3.01%)
ACST.VN : 0.470 (-6.00%)
Acasti Pharma Schedules Third Quarter Fiscal 2020 and Business Update Conference Call

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate...

ACST : 0.3346 (-3.01%)
ACST.VN : 0.470 (-6.00%)
Acasti Pharma Provides Update on TRILOGY 1 and TRILOGY 2 Phase 3 Trials of CaPre

Investigation underway into unexpected and inconsistent findings that may have negatively impacted results reported in TRILOGY 1

ACST : 0.3346 (-3.01%)
ACST.VN : 0.470 (-6.00%)
Acasti Pharma Reports Topline Results for TRILOGY 1 Phase 3 Trial of CaPre

Reports 30.5% and 36.7% reduction in triglyceride levels, compared with baseline, among patients receiving CaPre at 12 and 26 weeks respectively, as well as 42.2% reduction in triglyceride levels among...

ACST : 0.3346 (-3.01%)
ACST.VN : 0.470 (-6.00%)
IIROC Trading Resumption - ACST

Trading resumes in:

ACST : 0.3346 (-3.01%)
ACST.VN : 0.470 (-6.00%)
IIROC Trading Resumption - ACST

VANCOUVER , Dec. 24, 2019 /CNW/ - Trading resumes in:

ACST.VN : 0.470 (-6.00%)
Acasti Pharma Provides Update on Timing of Topline Results for TRILOGY 1 Phase 3 Trial of CaPre

Expects to report Trilogy 1 topline results in January 2020

ACST : 0.3346 (-3.01%)
ACST.VN : 0.470 (-6.00%)
IIROC Trading Halt - ACST

The following issues have been halted by IIROC:

ACST : 0.3346 (-3.01%)
ACST.VN : 0.470 (-6.00%)
IIROC Trading Halt - ACST

VANCOUVER , Dec. 23, 2019 /CNW/ - The following issues have been halted by IIROC:

ACST.VN : 0.470 (-6.00%)
Why the U.S. Remains the Largest Market for Medical Devices

Back in the end of 2018, a report from Moody's said that 2019 should be a standout year for the medical device industry. They added that revenue growth for device companies would be driven through innovation...

SOLY : 7.10 (-2.20%)
ATEC : 3.20 (-0.62%)
MDT : 86.27 (+0.14%)
IMGN : 3.42 (-1.44%)
ACST : 0.3346 (-3.01%)
ACST.VN : 0.470 (-6.00%)
Acasti Pharma Reports Last Patient Visit in TRILOGY 1 Phase 3 Trial of CaPre for the Treatment of Severe Hypertriglyceridemia

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate...

ACST : 0.3346 (-3.01%)
ACST.VN : 0.470 (-6.00%)
Why Oncology Drugs are Projected to Generate the Largest Pharma Revenues

A lot of cancer research is dealing with shrinking brain tumors and opening the door for targeted cancer therapies to work without damaging the surrounding tissue. The success rate for cancer therapies...

CNSP : 2.16 (+8.00%)
AMRN : 4.78 (-8.43%)
TEVA : 8.40 (+3.45%)
KRTX : 62.29 (-4.05%)
ACST : 0.3346 (-3.01%)
ACST.VN : 0.470 (-6.00%)
Acasti Pharma Releases Preliminary New Animal Data, and Gains Insights Into CaPre's Novel Mechanism of Action in Diabetes

-- Preliminary, statistically significant findings show that CaPre may promote insulin secretion, and showed a significant increase in plasma levels of 17S-HDHA and PDX as compared to metformin and icosapent...

ACST : 0.3346 (-3.01%)
ACST.VN : 0.470 (-6.00%)
Today's New Way to Fight Cancer Focusing on Metabolic Therapies

For decades researchers have been trying to find newer and more effective ways to fight cancer cells. Today much research is focused on attacking the cancerous cells growth. The reasoning is that denying...

MBRX : 0.5700 (+0.11%)
AMRN : 4.78 (-8.43%)
KDMN : 3.70 (-4.15%)
PFE : 33.64 (+2.34%)
ACST : 0.3346 (-3.01%)
ACST.VN : 0.470 (-6.00%)
Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2020

Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R)...

ACST : 0.3346 (-3.01%)
ACST.VN : 0.470 (-6.00%)
Acasti Pharma Announces Publication of CaPre Pharmacokinetics Study in a Leading Peer-Reviewed Journal

Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R)...

ACST : 0.3346 (-3.01%)
ACST.VN : 0.470 (-6.00%)
Acasti Pharma Schedules Second Quarter Fiscal 2020 Conference Call

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate...

ACST : 0.3346 (-3.01%)
ACST.VN : 0.470 (-6.00%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS -2.23 , SEDG -2.49 , THC -1.30 , TER -0.57 , LITE -3.30
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar